Impact of restarting warfarin therapy in renal disease anticoagulated patients with gastrointestinal hemorrhage

References

• Lip GY, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest. 2012;142(6):1489--1498
   PubMed Web of Science ®Google Scholar
• Winkelmayer WC, Liu J, Patrick AR, Setoguchi S, Choudhry NK. Prevalence of atrial fibrillation and warfarin use in older patients receiving hemodialysis. J Nephrol. 2012;25:341–353
   PubMed Web of Science ®Google Scholar
• Nelson SE, Shroff GR, Li S, Herzog CA. Impact of chronic kidney disease on risk of incident atrial fibrillation and subsequent survival in medicare patients. J Am Heart Assoc. 2012;1:e002097 . doi: 10.1161/JAHA.112.002097
   PubMed Web of Science ®Google Scholar
• Schonburg M, Ziegelhoeffer T, Weinbrenner F, et al. Preexisting atrial fibrillation as predictor for late-time mortality in patients with end-stage renal disease undergoing cardiac surgery – a multicenter study. Thoracic Cardiovascular Surgeon 2008;56:128–132
   PubMed Web of Science ®Google Scholar
• Laupacis A, Boysen G, Connolly S, et al. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Internal Med. 1994;154(13):1449–1457
   PubMedGoogle Scholar
• Collins AJ, Foley RN, Chavers B, et al. United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis: Official J Natl Kidney Foundation. 2012;59:A7, e1–e420
   PubMed Web of Science ®Google Scholar
• Sood P, Kumar G, Nanchal R, et al. Chronic kidney disease and end-stage renal disease predict higher risk of mortality in patients with primary upper gastrointestinal bleeding. Am J Nephrol. 2012;35:216–224
   PubMed Web of Science ®Google Scholar
• Coleman CI, Sobieraj DM, Winkler S, et al. Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation. Int J Clin Practice. 2012;66:53–63
   PubMed Web of Science ®Google Scholar
• McCullough K, Sharma P, Ali T, et al. Measuring the population burden of chronic kidney disease: a systematic literature review of the estimated prevalence of impaired kidney function. Nephrol Dialysis Transplant: Official Publ Eur Dialysis Transplant Assoc – Eur Renal Assoc. 2012;27:1812–1821
   Google Scholar
• Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32:2387–2394
   PubMed Web of Science ®Google Scholar
• Boland M, Murphy M, McDermott E. Acute-onset severe gastrointestinal tract hemorrhage in a postoperative patient taking rivaroxaban after total hip arthroplasty: a case report. J Med Case Rep. 2012;6:129
   PubMedGoogle Scholar
• Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864–2870
   PubMed Web of Science ®Google Scholar
• Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093-1100
   PubMed Web of Science ®Google Scholar
• Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Internal Med. 1999;130:461–470
   PubMed Web of Science ®Google Scholar
• Genovesi S, Vincenti A, Rossi E, et al. Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am J Kidney Dis: Official J Natl Kidney Foundation. 2008;51:255–262
   PubMed Web of Science ®Google Scholar
• To AC, Yehia M, Collins JF. Atrial fibrillation in hemodialysis patients: do the guidelines for anticoagulation apply? Nephrology (Carlton). 2007;12:441–447
   PubMed Web of Science ®Google Scholar
• Wizemann V, Tong L, Satayathum S, et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Intl. 2010;77:1098–1106
   PubMed Web of Science ®Google Scholar
• Nair M, Nayyar S, Rajagopal S, Balachander J, Kumar M. Results of radiofrequency ablation of permanent atrial fibrillation of >2 years duration and left atrial size >5 cm using 2-mm irrigated tip ablation catheter and targeting areas of complex fractionated atrial electrograms. Am J Cardiol. 2009;104:683–688
   PubMed Web of Science ®Google Scholar
• Pattakos G, Koch CG, Brizzio ME, et al. Outcome of patients who refuse transfusion after cardiac surgery: a natural experiment with severe blood conservation. Arch Internal Med. 2012;172:1154–1160
   PubMedGoogle Scholar
• Viviane A, Alan BN. Estimates of costs of hospital stay for variceal and nonvariceal upper gastrointestinal bleeding in the United States. Value Health: J Intl Soc Pharmacoecon Outcomes Res. 2008;11:1–3
   Google Scholar
• Andrassy K, Ritz E. Uremia as a cause of bleeding. Am J Nephrol. 1985;5:313–319
   PubMed Web of Science ®Google Scholar
• Sagripanti A, Barsotti G. Bleeding and thrombosis in chronic uremia. Nephron 1997;75:125–139
   PubMed Web of Science ®Google Scholar
• Linne T. Prolonged bleeding time in non-uremic acute glomerulonephritis. Thrombosis Hemostasis 1979;42:1060–1061
   PubMed Web of Science ®Google Scholar
• Sagedal S, Hartmann A, Sundstrom K, Bjornsen S, Brosstad F. Anticoagulation intensity sufficient for hemodialysis does not prevent activation of coagulation and platelets. Nephrol Dialysis Transplant: Official Publ Eur Dialysis Transplant Assoc – Eur Renal Assoc. 2001;16:987–993
   Google Scholar
• Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009;20:2223–2233
   PubMed Web of Science ®Google Scholar
• Kussmaul W. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease. Ann Internal Med. 2012;157:302; author reply 3–4
   PubMed Web of Science ®Google Scholar
• Erdem Y, Haznedaroglu IC, Celik I, et al. Coagulation, fibrinolysis and fibrinolysis inhibitors in hemodialysis patients: contribution of arteriovenous fistula. Nephrol Dialysis Transplant: Official Publ Eur Dialysis Transplant Assoc – Eur Renal Assoc. 1996;11:1299–1305
   Google Scholar
• Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Intl. 1995;47:186–192
   PubMed Web of Science ®Google Scholar
• Knight TG, Ryan K, Schaefer CP, D'Sylva L, Durden ED. Clinical and economic outcomes in Medicare beneficiaries with stage 3 or stage 4 chronic kidney disease and anemia: the role of intravenous iron therapy. JMCP. 2010;16:605–615
   PubMed Web of Science ®Google Scholar
• Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Internal Med. 2005;143:241–250
   PubMed Web of Science ®Google Scholar
• Schreiber TL, Miller DH, Silvasi D, McNulty A, Zola BE. Superiority of warfarin over aspirin long term after thrombolytic therapy for acute myocardial infarction. Am Heart J. 1990;119:1238–1244
   PubMed Web of Science ®Google Scholar